Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo

Biomedicine and Pharmacotherapy

Volumn 66, Issue 1, 2012, Pages 12-20

  Kuo, Yu Cheng ^a,b,c   Lin, Wei Chan ^a,d   Chiang, I Tsang ^a   Chang, Ya Fang ^a   Chen, Chia Wen ^b   Su, Shih Hao ^a   Chen, Chuan Lin ^a   Hwang, Jeng Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Human colorectal carcinoma; NF B; Radiosensitization; Sorafenib

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SORAFENIB;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CULTURE; CELL CYCLE; CHEMORADIOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; GEL MOBILITY SHIFT ASSAY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; NF-KAPPA B; PYRIDINES; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862777510     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.09.011     Document Type: Article

References (30)

1. Annual reports of the Department of Health, the Executive Yuan, Republic of China; 2004.
2. Crane C.H., Skibber J.M., Birnbaum E.H., Feig B.W., Singh A.K., Delclos M.E., et al. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2003, 57:84-89.
3. Bosset J.F., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol 2005, 23:5620-5627.
4. Janjan N.A., Crane C., Feig B.W., Cleary K., Dubrow R., Curley S., et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001, 24:107-112.
5. Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
6. Gupta A.K., Bakanauskas V.J., Cerniglia G.J., Cheng Y., Bernhard E.J., Muschel R.J., et al. The Ras radiation resistance pathway. Cancer Res 2001, 61:4278-4282.
7. Kunnumakkara A.B., Diagaradjane P., Guha S., Deorukhkar A., Shentu S., Aggarwal B.B., et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 2008, 14:2128-2136.
8. Sandur S.K., Deorukhkar A., Pandey M.K., Pabon A.M., Shentu S., Guha S., et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys 2009, 75:534-542.
9. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010, 1805:167-180.
10. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12:7271-7278.
11. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
12. Wilhelm S., Chien D.S. BAY 43-9006: preclinical data. Curr Pharm Des 2002, 8:2255-2257.
13. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
14. Yu C., Bruzek L.M., Meng X.W., Gores G.J., Carter C.A., Kaufmann S.H., et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24:6861-6869.
15. Su J.L., Yen C.J., Chen P.S., Chuang S.E., Hong C.C., Kuo I.H., et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007, 96:541-545.
16. Hellstrom M., Kalen M., Lindahl P., Abramsson A., Betscholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
17. Chang Y.F., Lin Y.Y., Wang H.E., Liu R.S., Pang F., Hwang J.J. Monitoring of tumor growth and metastasis potential in MDA-MB-435s/tk-luc human breast cancer xenografts. Nucl Instrum Methods Phys Res 2007, 571:155-159.
18. Bankston D., Dumas J., Natero R., Riedl B., Monahan M.K., Sibley R. A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer. Organic Process Res Dev 2002, 6:777-781.
19. Valeriote F., Lin H. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep 1975, 59:895-900.
20. Carpentier Y., Demange L., Loirette M., Hivet J., Desoize B. Chronology of combined chemotherapy (5FU) and radiotherapy. I. In vitro study. Anticancer Res 1993, 13:2177-2180.
21. Chow T.H., Lin Y.Y., Hwang J.J., Wang H.E., Tseng Y.L., Pang V.F., et al. Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 2008, 35:623-634.
22. Chow T.H., Lin Y.Y., Hwang J.J., Wang H.E., Tseng Y.L., Pang V.F., et al. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med 2009, 50:2073-2081.
23. Cheng J.C., Chou C.H., Kuo M.L., Hsieh C.Y. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006, 25:7009-7018.
24. Valerie K., Yacoub A., Hagan M.P., Curiel D.T., Fisher P.B., Grant S., et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007, 6:789-801.
25. Dent P., Yacoub A., Fisher P.B., Hagan M.P., Grant MAPK pathways in radiation responses. Oncogene 2003, 22:5885-5896.
26. Machtay M., Moughan J., Trotti A., Garden A.S., Weber R.S., Cooper J.S., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008, 26:3582-4359.
27. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
28. Plastaras J.P., Kim S.H., Liu Y.Y., Dicker D.T., Dorsey J.F., McDonough J., et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007, 67:9443-9454.
29. Suen A.W., Galoforo S., Marples B., McGonagle M., Downing L., Martinez A.A., et al. Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys 2010, 78:213-220.
30. Kasibhatla M., Steinberg P., Meyer J., Ernstoff M.S., George D.J. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007, 5:291-294.